Amarantus Therapeutics Obtains European Patent Notice of Allowance Covering Discovery of Lead Protein MANF
Published: Jul 28, 2010
SUNNYVALE, CA--(Marketwire - July 28, 2010) - Amarantus Therapeutics, Inc., a privately-held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, has received a Notice of Allowance from the European Patent Office (EPO). The patent application claims include the discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF), a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of a range of diseases that includes Parkinson's disease. The patent will broaden overall protection for the Company's therapeutic development of MANF.
The patent claims include compositions of matter and methods of use for MANF, and other related compounds. This new patent complements Amarantus' existing collection of pending patent applications on its proprietary platforms.
"This initial patent allowance from the EPO is a major milestone for the Company's intellectual property pursuits and significantly strengthens our proprietary position in the field," said Martin D. Cleary, Chief Executive Officer. "Moreover, this latest patent will further protect Amarantus' intellectual property as the Company expands its pipeline of first-in-class therapeutics to address a number of indications. Additionally, we will continue to build a strong intellectual property portfolio around our proprietary technology and to further strengthen our leadership position in the emerging field of novel therapeutics."
About Amarantus Therapeutics, Inc.
Amarantus Therapeutics, Inc. is a privately-held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company's most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson's disease and Myocardial Infarction. Currently incubating at the Parkinson's Institute, Amarantus Therapeutics is a recipient of a research grant from The Michael J. Fox Foundation for Parkinson's Research. The Company is currently fund raising to advance its lead programs into clinical development. www.amarantustherapeutics.com
Erik Clausen or Kena Hudson
College Hill, Inc. for Amarantus Therapeutics, Inc.
Erik.Clausen@CollegeHill.com or Kena.Hudson@CollegeHill.com